Corcept Therapeutics Incorporated (CORT) Financial Statements
Corcept Therapeutics Incorporated (CORT) reported trailing twelve-month revenue of $830.8M (up 16.0% year on year) and net income of $55.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $106.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CORTCorcept Therapeutics IncorporatedFollow CORT — free
—
Price chart with a free account
- Market cap
- 9.3B
- P/E TTM
- 204.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2009 Dec 09 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 251.2 | 306.5 | 353.9 | 366.0 | 401.9 | 482.4 | 675.0 | 761.4 | 830.8 | |
| Gross profit | — | 246.0 | 301.0 | 348.3 | 360.7 | 396.5 | 475.9 | 664.2 | 748.4 | — | |
| Research & development | — | 75.2 | 89.0 | 114.8 | 113.9 | 131.0 | 184.4 | 246.9 | 254.9 | 253.9 | |
| Operating income | — | 89.5 | 111.6 | 128.2 | 124.5 | 112.6 | 107.3 | 137.0 | 44.8 | 6.4 | |
| Pre-tax income | — | 92.2 | 116.7 | 131.6 | 125.0 | 116.2 | 124.6 | 161.5 | 66.5 | 26.4 | |
| Income tax | — | 16.7 | 22.5 | 25.6 | 12.5 | 14.8 | 18.4 | 20.3 | -33.2 | -28.8 | |
| Net income | -20.2 | 75.4 | 94.2 | 106.0 | 112.5 | 101.4 | 106.1 | 141.2 | 99.7 | 55.2 | |
| Diluted EPS ($) | — | 0.60 | 0.77 | 0.85 | 0.89 | 0.87 | 0.94 | 1.23 | 0.82 | 0.42 | |
| Diluted shares (mn) | — | 126.7 | 122.6 | 124.2 | 126.0 | 116.0 | 111.7 | 113.5 | 120.0 | — |
USD millions · SEC XBRL
Corcept Therapeutics Incorporated — questions
- What is Corcept Therapeutics Incorporated's revenue?
- $830.8M over the twelve months to 2026-06-30, up 16.0% year on year, from its 10-Q and 10-K filings.
- What is Corcept Therapeutics Incorporated's net income?
- $55.2M over the twelve months to 2026-06-30.
- What is Corcept Therapeutics Incorporated's free cash flow?
- $106.9M over the twelve months to 2026-06-30.
- What are Corcept Therapeutics Incorporated's diluted earnings per share?
- $0.42 over the twelve months to 2026-06-30.
Every figure on this page comes from Corcept Therapeutics Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.